Royal Bank of Canada
GRCE

Royal Bank of Canada’s Grace Therapeutics GRCE Stock Holding History

Royal Bank of Canada’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Hold
543
– – ﹤0.01% 7298
2026
Q1 		$3K Hold
543
– – ﹤0.01% 6636
2025
Q4 		$2K Sell
543
-28
-5% -$89 ﹤0.01% 6943
2025
Q3 		$2K Buy
571
+28
+5% +$88 ﹤0.01% 6932
2025
Q2 		$2K Hold
543
– – ﹤0.01% 6837
2025
Q1 		$1K Sell
543
-3
-0.5% -$9 ﹤0.01% 6743
2024
Q4 		$2K Buy
546
+3
+0.6% +$10 ﹤0.01% 6743
2024
Q3 		$2K Sell
543
-6,041
-92% -$16.1K ﹤0.01% 6670
2024
Q2 		$20K Sell
6,584
-6,000
-48% -$18.1K ﹤0.01% 6085
2024
Q1 		$43K Sell
12,584
-19,000
-60% -$56K ﹤0.01% 5607
2023
Q4 		$92K Buy
31,584
+31,000
+5,308% +$73.4K ﹤0.01% 5667
2023
Q3 		$2K Sell
584
-1
-0.2% -$2 ﹤0.01% 6827
2023
Q2 		$2K Hold
585
– – ﹤0.01% 6919
2023
Q1 		$2K Buy
585
+301
+106% +$1.08K ﹤0.01% 6814
2022
Q4 		$1K Buy
284
+100
+54% +$295 ﹤0.01% 7101
2022
Q3 		$1K Buy
184
+118
+179% +$582 ﹤0.01% 7306
2022
Q2 		$0 Buy
66
+28
+74% +$170 ﹤0.01% 7796
2022
Q1 		$0 Sell
38
-313
-89% -$2.23K ﹤0.01% 8094
2021
Q4 		$3K Buy
351
+192
+121% +$1.73K ﹤0.01% 7355
2021
Q3 		$2K Buy
159
+113
+246% +$2.23K ﹤0.01% 7373
2021
Q2 		$1K Buy
46
+2
+5% +$49 ﹤0.01% 7359
2021
Q1 		$1K Hold
44
– – ﹤0.01% 7335
2020
Q4 		$1K Hold
44
– – ﹤0.01% 6983
2020
Q3 		$0 Sell
44
-91
-67% -$2.36K ﹤0.01% 6987
2020
Q2 		$3K Buy
135
+59
+78% +$1.72K ﹤0.01% 6221
2020
Q1 		$1K Buy
76
+16
+27% +$567 ﹤0.01% 6507
2019
Q4 		$7K Buy
60
+17
+40% +$1.68K ﹤0.01% 6264
2019
Q3 		$4K Sell
43
-43
-50% -$3.98K ﹤0.01% 6129
2019
Q2 		$5K Sell
86
-91
-51% -$4K ﹤0.01% 6338
2019
Q1 		$9K Buy
177
+92
+108% +$4.54K ﹤0.01% 6051
2018
Q4 		$3K Hold
85
– – ﹤0.01% 6375
2018
Q3 		$5K Sell
85
-29
-25% -$805 ﹤0.01% 6287
2018
Q2 		$3K Buy
114
+29
+34% +$1.11K ﹤0.01% 6190
2018
Q1 		$4K Buy
85
+83
+4,150% +$4.1K ﹤0.01% 6004
2017
Q4 		$0 Hold
2
– – ﹤0.01% 6955
2017
Q3 		$0 Hold
2
– – ﹤0.01% 7035
2017
Q2 		$0 Hold
2
– – ﹤0.01% 6809
2017
Q1 		$0 Hold
2
– – ﹤0.01% 6858
2016
Q4 		$0 Hold
2
– – ﹤0.01% 6814
2016
Q3 		$0 Sell
2
-10
-83% -$740 ﹤0.01% 6609
2016
Q2 		$1K Hold
12
– – ﹤0.01% 6278
2016
Q1 		$1K Hold
12
– – ﹤0.01% 6244
2015
Q4 		$1K Buy
12
+2
+20% +$236 ﹤0.01% 6503
2015
Q3 		$1K Buy
10
+8
+400% +$1.34K ﹤0.01% 6522
2015
Q2 		$0 Sell
2
-4
-67% -$744 ﹤0.01% 6749
2015
Q1 		$1K Buy
6
+2
+50% +$471 ﹤0.01% 6004
2014
Q4 		$1K Hold
4
– – ﹤0.01% 6061
2014
Q3 		$1K Hold
4
– – ﹤0.01% 5883
2014
Q2 		$2K Hold
4
– – ﹤0.01% 5738
2014
Q1 		$2K Hold
4
– – ﹤0.01% 5744
2013
Q4 		$3K Hold
4
– – ﹤0.01% 5721
2013
Q3 		$5K Buy
4
+2
+100% +$2.98K ﹤0.01% 5640
2013
Q2 		$3K Buy
+2
New +$2.41K ﹤0.01% 5563

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Royal Bank of Canada's GRCE Position: Q2 2026 in Review

Royal Bank of Canada held its Grace Therapeutics (GRCE) position steady in Q2 2026 at 543 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7298.

Royal Bank of Canada first reported a position in GRCE in Q2 2013 and has held it in 53 quarters since. The position peaked at $92K in Q4 2023. 31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Royal Bank of Canada held 543 shares of Grace Therapeutics worth $1K as of Q2 2026.
  • Royal Bank of Canada left its Grace Therapeutics share count unchanged in Q2 2026.
  • Grace Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7298 holding.
  • Royal Bank of Canada first reported a position in Grace Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's Grace Therapeutics position peaked at $92K in Q4 2023.
  • 31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.